Barclays Raises FedEx Price Target to $360 on Growth Outlook
Barclays maintained its Overweight rating for FedEx Corporation (NYSE:FDX) and raised its price target from $320 to $360 on December 16, 2025. The adjustment reflects confidence in the global logistics leader despite the stock currently maintaining a hold status among analysts.
Institutional investors have recently expanded their positions in the company. B. Riley Wealth Advisors Inc. acquired 4,865 shares valued at $1.11 million USD. Valeo Financial Advisors LLC increased its holdings to 3.74 million shares with an approximate value of $851 million USD.
Other major financial institutions reporting increased exposure include:
- Norges Bank established a new position valued at $605 million USD during the second quarter.
- AQR Capital Management LLC expanded its holdings by 750.9% to own more than one million shares.
FedEx shares were trading at $281.72 on December 16, 2025, representing a 0.2% increase. The stock reached an intraday high of $282.99 and a low of $281.08. Over the last 52 weeks, the equity has traded between $194.30 and $295.24.
The company maintains a market capitalization of $66.47 billion USD. FedEx provides transportation and e-commerce services, competing with United Parcel Service and DHL. More details are available in the FDX financial summary and the FDX.
Information regarding the company operations can be found in the FDX and FDX reports. Analysis of the current balance sheet is documented in the FDX blog.
FedEx Corporation (FDX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.